Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Clin Cancer Res
; 26(1): 242-255, 2020 01 01.
Article
in En
| MEDLINE
| ID: mdl-31585938
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lactams, Macrocyclic
/
Anaplastic Lymphoma Kinase
/
Lung Neoplasms
Type of study:
Observational_studies
Limits:
Adult
/
Animals
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2020
Document type:
Article
Affiliation country:
France
Country of publication:
United States